Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 2/2018

01-04-2018 | Review

Influenza and the patient with end-stage renal disease

Authors: Brendan T. Bowman, Mitchell H. Rosner

Published in: Journal of Nephrology | Issue 2/2018

Login to get access

Abstract

Influenza is a commonly encountered and serious pathogen. Patients with end-stage renal disease are more susceptible to serious morbidity and mortality associated with influenza infection. Proper management of patients includes: vaccination, monitoring for symptoms and isolation of potentially infected patients as well as appropriate antiviral therapies. In some cases of exposure, chemoprophylaxis is warranted. Vaccination and appropriate therapies are associated with improved outcomes.
Literature
1.
Thompson MG et al (2010) Estimates of deaths associated with seasonal influenza—United States 1976–2007. MMWR 59:1057–1062
2.
World Health Organization (2009) Pandemic influenza preparedness and response: a WHO guidance document. WHO, Geneva
3.
Prevention and Control of Seasonal Influenza with Vaccines (2016) Recommendations of the advisory committee on immunization practices—United States, 2016–2017 influenza season. MMWR 65:1–52CrossRef
4.
Treanor J (2015) In: Bennett JE (ed) Influenza principles and practice of infectious diseases, 8th edn. Elsevier, Philadelphia
5.
De Clerq E (2007) Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharm Sci 28(6):280–285
6.
Cohen YZ, Dolin R (2015) Influenza. In: Kasper D et al (eds) Harrison’s principles of internal medicine, 19th Edn. McGraw-Hill Education, USA
7.
Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influneza viruses. Nat Rev Immunol 7:267–278CrossRefPubMed
8.
York I, Donis RO (2012) The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going? CRRN Top Mirc Immun 370:241–257
9.
Shrestha S et al (2011) Estimating the burden of 2009 pandemic influneza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis 52(Supplement):S75–S82CrossRefPubMed
10.
United States Renal Data System (2016) 2016 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
11.
Betjes MG (2013) Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 9:255–265CrossRefPubMed
12.
Eleftheriadis T et al (2007) Disturbances in acquired immunity in hemodialysis patients. Semin Dial 20:440–451CrossRefPubMed
13.
Hauser AB et al (2007) Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 28(Supplement 3):S183–S187
14.
Soni R, Horowitz B, Unruh M (2013) Immunization in end-stage renal disease: opportunity to improved outcomes. Semin Dial 26:416–426CrossRefPubMed
15.
Jordan MC et al (1973) Immunogenicity of inactivated influenza virus vaccine in chronic renal failure. Ann Intern Med 79:790–794CrossRefPubMed
16.
Ortbals DW (1978) Influenza immunization in patients with chronic renal disease. JAMA 239:2562–2565CrossRefPubMed
17.
Antonen JA et al (2000) Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 86:56–61CrossRefPubMed
18.
Antonen JA et al (2003) Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol Dial Transplant 18:777–781CrossRefPubMed
19.
Dinits-Pensy M et al (2005) The use of vaccines in adult patients with renal disease. AJKD 46:997–1011CrossRefPubMed
20.
21.
Labriola L et al (2011) Immunocgenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in heamodialysed patients. NDT 26:1424–1428PubMed
22.
Gilbertson DT et al (2003) Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 63:738–743CrossRefPubMed
23.
Bond TC, Spaulding AC, Krisher J, McClellan W (2012) Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 60:959–965CrossRefPubMed
24.
McGrath LJ et al (2012) Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 172:548–554CrossRefPubMedPubMedCentral
25.
Wang I et al (2016) Seasonal influenza vaccination is associated with reduced morbidity and mortality in peritoneal dialysis patients. NDT 31:269–274PubMed
26.
Wetmore JB, PEER Kidney Care Initiative Investigators (2016) Trends in infection in dialysis patients. AJKD 67:A13CrossRef
27.
Remschmidt C, Wichmann O, Harder T (2014) Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med 12:1–14CrossRef
28.
Wiebe C et al (2009) Atypical clinical presentation of H1N1 influenza in a dialysis patient. Lancet 374:1300CrossRefPubMed
29.
Marcelli D, Marelli C, Richards N (2009) Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant 24:3566–3572CrossRefPubMed
30.
Li H, Wang SX (2010) Clinical features of 2009 pandemic influenza A (H1N1) virus infection in chronic hemodialysis patients. Blood Purif 30:172–177CrossRefPubMed
31.
Cho JH et al (2011) Impact of dialysis modality on the incidence of 2009 pandemic H1N1 influenza in end-stage renal disease patients. Perit Dial Int 31:347–350CrossRefPubMed
32.
Peer Kidney Care Initiative (2015) Seasonality of hospitalization for pneumonia, influenza, and dialysis access infection. AJKD 65:A67
33.
Wakasugi M (2012) High mortality rate of infectious diseases in dialysis patients: a comparison with the general population in Japan. Ther Apher Dial 16:226–231CrossRefPubMed
34.
ACIP (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR 60(1):1–24
35.
Thomas B, Hollister AS, Muczynski KA (2010) Peramivir clearance in continuous renal replacement therapy. Hemodial Int 14:339–340CrossRefPubMed
36.
Robson R et al (2006) The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephol Dial Transplant 21:2556–2562CrossRef
37.
Patel K et al (2014) Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. Br J Clin Pharmacol 79:624–635CrossRefPubMedCentral
38.
Eyler RF, Heung M, Pleva M (2012) Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy 32:1061–1069CrossRefPubMed
39.
Taylor WR, Thinh BN, Anh GT (2008) Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3:e3410CrossRefPubMedPubMedCentral
40.
Flannery AH, Thomson B ML (2014) Oseltamivir dosing in critically Ill patients with severe influenza. Ann Pharamcotherapy 48:1011–1018CrossRef
41.
42.
43.
Bazan JA et al (2010) Peramivir pharmacokinetics in two critically ill adult patients with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. Pharmacotherapy 10:1016–1020CrossRef
44.
Bentley ML et al (2014) Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. Int J Clin Pharmacol Ther 52:1105–1111CrossRefPubMed
45.
Scheetz MH et al (2011) Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. Ann Pharmacother 45(12):E64CrossRefPubMed
46.
Harper SA et al (2008) Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the infectious disease society of America. Clin Infect Dis 48:1003–1032CrossRef
Metadata
Title
Influenza and the patient with end-stage renal disease
Authors
Brendan T. Bowman
Mitchell H. Rosner
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 2/2018
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-017-0407-9

Other articles of this Issue 2/2018

Journal of Nephrology 2/2018 Go to the issue

Review

Predicting acute kidney injury: current status and future challenges

Original Article

Isolated pancreas rejections do not have an adverse impact on kidney graft survival whereas kidney rejections are associated with adverse pancreas graft survival in simultaneous pancreas kidney transplantation

Original Article

Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases

Original Article

Quality of life following hospitalization-associated acute kidney injury in children

Original Article

A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?

Original Article

Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits